JP2024520205A5 - - Google Patents
Info
- Publication number
- JP2024520205A5 JP2024520205A5 JP2023571857A JP2023571857A JP2024520205A5 JP 2024520205 A5 JP2024520205 A5 JP 2024520205A5 JP 2023571857 A JP2023571857 A JP 2023571857A JP 2023571857 A JP2023571857 A JP 2023571857A JP 2024520205 A5 JP2024520205 A5 JP 2024520205A5
- Authority
- JP
- Japan
- Prior art keywords
- modified oligonucleotide
- nucleic acid
- modified
- oligomer compound
- oligomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191905P | 2021-05-21 | 2021-05-21 | |
| US63/191,905 | 2021-05-21 | ||
| PCT/US2022/030335 WO2022246251A2 (en) | 2021-05-21 | 2022-05-20 | Compounds for modulating unc13a expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520205A JP2024520205A (ja) | 2024-05-22 |
| JP2024520205A5 true JP2024520205A5 (https=) | 2025-05-26 |
Family
ID=84140868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571857A Pending JP2024520205A (ja) | 2021-05-21 | 2022-05-20 | Ｕｎｃ１３ａの発現を調節するための化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240301415A1 (https=) |
| EP (1) | EP4341406A4 (https=) |
| JP (1) | JP2024520205A (https=) |
| WO (1) | WO2022246251A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2603454A (en) * | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
| WO2023004049A1 (en) * | 2021-07-21 | 2023-01-26 | AcuraStem, Inc. | Unc13a antisense oligonucleotides |
| GB202117758D0 (en) * | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
| JP2025500335A (ja) * | 2021-12-21 | 2025-01-09 | エフ． ホフマン－ラ ロシュ アーゲー | Ｕｎｃ１３ａを標的とするアンチセンスオリゴヌクレオチド |
| AU2023356317A1 (en) * | 2022-10-05 | 2025-05-15 | Trace Neuroscience, Inc. | Unc13a antisense oligonucleotides and uses thereof |
| WO2024178223A1 (en) * | 2023-02-24 | 2024-08-29 | Northwestern University | Antisense oligonucleotides for preventing unc13a misplicing |
| WO2024220746A2 (en) | 2023-04-21 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting fatty acid synthase and related methods |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025178854A2 (en) | 2024-02-19 | 2025-08-28 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting cideb and related methods |
| US12612630B2 (en) | 2024-03-05 | 2026-04-28 | Takeda Pharmaceutical Company Limited | Compositions and methods for splicing modulation of UNC13A |
| WO2025217275A2 (en) | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Immune cell targeted compositions and related methods |
| WO2026080323A1 (en) * | 2024-10-09 | 2026-04-16 | Quralis Corporation | Treatment of neurological diseases using modulators of unc13a gene transcripts |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69435005T2 (de) * | 1993-05-11 | 2008-04-17 | The University Of North Carolina At Chapel Hill | Antisense Oligonukleotide die anomales Splicing verhindern und deren Verwendung |
| EP1470423A2 (en) * | 2001-11-05 | 2004-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Unc-13 in the modulation of neurotransmission and secretion events |
| AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| WO2005116204A1 (ja) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| US20110195848A1 (en) * | 2010-01-08 | 2011-08-11 | Roopra Avtar S | Gene expression and breast cancer |
| US10517889B2 (en) * | 2017-09-08 | 2019-12-31 | Ionis Pharmaceuticals, Inc. | Modulators of SMAD7 expression |
| GB2603454A (en) * | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
-
2022
- 2022-05-20 EP EP22805616.4A patent/EP4341406A4/en active Pending
- 2022-05-20 US US18/562,543 patent/US20240301415A1/en active Pending
- 2022-05-20 WO PCT/US2022/030335 patent/WO2022246251A2/en not_active Ceased
- 2022-05-20 JP JP2023571857A patent/JP2024520205A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024520205A5 (https=) | ||
| JP2024539596A5 (https=) | ||
| RU2566724C9 (ru) | Композиции и способы модуляции smn2 сплайсинга у субъекта | |
| JP2020196751A (ja) | 筋強直性ジストロフィーを治療するためのペプチド結合モルホリノアンチセンスオリゴヌクレオチド | |
| JP2024504377A5 (https=) | ||
| JP2023536472A5 (https=) | ||
| JP2022518929A5 (https=) | ||
| JP2022533358A5 (https=) | ||
| JP2017533715A (ja) | 調節性ポリヌクレオチド | |
| KR20080031164A (ko) | ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절 | |
| HRP20020309A2 (en) | Treatment of fatigue, head injury and stroke | |
| HUE028036T2 (en) | Tricyclic DNA anti-sense oligonucleotides, compositions and methods for treating a disease | |
| JP2024523363A5 (https=) | ||
| JP2023536994A5 (https=) | ||
| RU2008130855A (ru) | ОПОСРЕДОВАННОЕ РНКI ИНГИБИРОВАНИЕ Rho-КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ НАРУШЕНИЙ | |
| JP2024540537A5 (https=) | ||
| RS66986B1 (sr) | Antisense lečenje angelmanovog sindroma | |
| JP2021534154A5 (https=) | ||
| CN104080910A (zh) | 使用微rna195提供神经保护作用的方法 | |
| JP2022500079A5 (https=) | ||
| JP2022515140A5 (https=) | ||
| JP2024506351A5 (https=) | ||
| JP2023530072A5 (https=) | ||
| JP2023528755A5 (https=) | ||
| WO2026026776A1 (zh) | 抑制APP基因表达的siRNA及其缀合物和应用 |